303 related articles for article (PubMed ID: 21824038)
1. TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.
Eckhoff L; Nielsen M; Moeller S; Knoop A
Acta Oncol; 2011 Oct; 50(7):1075-82. PubMed ID: 21824038
[TBL] [Abstract][Full Text] [Related]
2. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
[TBL] [Abstract][Full Text] [Related]
3. Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
Miguel I; Winckler P; Sousa M; Cardoso C; Moreira A; Brito M
Breast Dis; 2015; 35(3):167-71. PubMed ID: 26406541
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
[TBL] [Abstract][Full Text] [Related]
5. Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide.
Montella L; Addeo R; Guarrasi R; Cennamo G; Faiola V; Capasso E; Caraglia M; Del Prete S
Eur J Cancer Care (Engl); 2010 Mar; 19(2):200-4. PubMed ID: 19552732
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
7. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
Margolin S; Bengtsson NO; Carlsson L; Edlund P; Hellstrøm M; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmström P; Pettersson Skøld D; Søderberg M; Villman K; Bergh J;
Acta Oncol; 2011 Jan; 50(1):35-41. PubMed ID: 21174610
[TBL] [Abstract][Full Text] [Related]
8. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
Ottosson S; Magnusson K; Hultborn R
Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
[TBL] [Abstract][Full Text] [Related]
9. Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.
Assi H; Murray J; Boyle L; Rayson D
Support Care Cancer; 2014 Dec; 22(12):3227-34. PubMed ID: 24996828
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.
Sanna G; Pestrin M; Zafarana E; Biagioni C; Cavaciocchi D; Turner N; Di Leo A; Biganzoli L
Breast; 2013 Oct; 22(5):926-32. PubMed ID: 23707082
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
[TBL] [Abstract][Full Text] [Related]
12. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
[TBL] [Abstract][Full Text] [Related]
13. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
[TBL] [Abstract][Full Text] [Related]
15. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Roché H; Fumoleau P; Spielmann M; Canon JL; Delozier T; Serin D; Symann M; Kerbrat P; Soulié P; Eichler F; Viens P; Monnier A; Vindevoghel A; Campone M; Goudier MJ; Bonneterre J; Ferrero JM; Martin AL; Genève J; Asselain B
J Clin Oncol; 2006 Dec; 24(36):5664-71. PubMed ID: 17116941
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study.
Freyer G; Campone M; Peron J; Facchini T; Terret C; Berdah JF; Jacquin JP; Coeffic D; Hilaire Pde S; Falandry C
Crit Rev Oncol Hematol; 2011 Dec; 80(3):466-73. PubMed ID: 21565521
[TBL] [Abstract][Full Text] [Related]
17. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
[TBL] [Abstract][Full Text] [Related]
18. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
Papaldo P; Lopez M; Marolla P; Cortesi E; Antimi M; Terzoli E; Vici P; Barone C; Ferretti G; Di Cosimo S; Carlini P; Nisticò C; Conti F; Di Lauro L; Botti C; Di Filippo F; Fabi A; Giannarelli D; Calabresi F
J Clin Oncol; 2005 Oct; 23(28):6908-18. PubMed ID: 16129844
[TBL] [Abstract][Full Text] [Related]
19. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide.
Andersen KG; Jensen MB; Kehlet H; Gärtner R; Eckhoff L; Kroman N
Acta Oncol; 2012 Nov; 51(8):1036-44. PubMed ID: 22676048
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.
Fabi A; Papaldo P; Pino MS; Ferretti G; Carlini P; Pacetti U; Di Cosimo S; Nardoni C; Giannarelli D; Sacchi I; Cognetti F
Anticancer Res; 2004; 24(3b):1963-7. PubMed ID: 15274385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]